Zi Hui

Dr. Zi Hui

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JDJi-Long Duan
Ji-Long Duan
CWChen-Chen Wang
Chen-Chen Wang
YYYinghui Yuan
Yinghui Yuan
ZHZi Hui
Zi Hui
HZHang Zhang
Hang Zhang
XYXiang-Yang Ye
Xiang-Yang Ye

10 February 2021 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
SHSuwen Hu
Suwen Hu
ZHZi Hui
Zi Hui
FLFrédéric Lirussi
Frédéric Lirussi
GCGarrido Carmen
Garrido Carmen
XYXiang-Yang Ye
Xiang-Yang Ye
TXTian Xie
Tian Xie
Introduction: DNA-dependent protein kinase (DNA-PK) plays a crucial role in the repair of DSBs via non-homologous end joining (NHEJ). Several DNA-PK inhibitors are being investigated for potential anticancer treatment in clinical trials. Area covered: This review aims to give an overview of patents published since 2010 by analyzing the patent space and structure features of scaffolds used in those patents. It also discusses the recent clinical developments and provides perspectives on future challenges and directions in this field. Expert opinion: As a key component of the DNA damage response (DDR) pathway, DNA-PK appears to be a viable drug target for anticancer therapy. The clinical investigation of a DNA-PK inhibitor employs both a monotherapy and a combination strategy. In the combination strategy, a DNA-PK inhibitor is typically combined with a DSB inducer, radiation, a chemotherapy agent, or a PARP inhibitor, etc. Patent analyses suggest that diverse structures comprising different scaffolds from mono-heteroaryl to bicyclic heteroaryl to tricyclic heteroaryl are capable to achieve good DNA-PK inhibitory activity and good DNA-PK selectivity over other closely related enzymes. Several DNA-PK inhibitors are currently being evaluated in clinics, with the hope to get approval in the near future.

4 September 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JLJunjie Li
Junjie Li
RZRui Zhao
Rui Zhao
PMPeiran Miao
Peiran Miao
FXFengfeng Xu
Fengfeng Xu
JCJiahao Chen
Jiahao Chen
Renren BaiRenren Bai
Renren Bai

12 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
LWLiwei Wang
Liwei Wang
SJSongwei Jiang
Songwei Jiang
YYYing-Hui Yuan
Ying-Hui Yuan
JDJilong Duan
Jilong Duan
NMNian-Dong Mao
Nian-Dong Mao
XYXiang-Yang Ye
Xiang-Yang Ye
As one of the key phosphatidylinositol 3-kinase-related kinases (PIKKs) family members, ataxia telangiectasia and RAD3-related protein kinase (ATR) is crucial in maintaining mammalian cell genomic integrity in DNA damage response (DDR) and repair pathways. Dysregulation of ATR has been found across different cancer types. In recent years, the inhibition of ATR has been proven to be effective in cancer therapy in preclinical and clinical studies. Importantly, tumor-specific alterations such as ATM loss and Cyclin E1 (CCNE1) amplification are more sensitive to ATR inhibition and are being exploited in synthetic lethality (SL) strategy. Besides SL, synergistic anticancer effects involving ATRi have been reported in an increasing number in recent years. This review focuses on the recent advances in different forms of synergistic antitumor effects, summarizes the pharmacological benefits and ongoing clinical trials behind the biological mechanism, and provides perspectives for future challenges and opportunities. The hope is to draw awareness to the community that targeting ATR should have great potential in developing effective anticancer medicines.

2 December 2022 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
JDJinyun Dong
Jinyun Dong
JDJilong Duan
Jilong Duan
ZHZi Hui
Zi Hui
GCGarrido Carmen
Garrido Carmen
ZDZhangshuang Deng
Zhangshuang Deng
XYXiang-Yang Ye
Xiang-Yang Ye
Protein arginine methyltransferases (PRMTs), enzymes catalyzing the methylation of target proteins, play an essential role in maintaining functional homeostasis in normal physiology. Aberrant expressions and enhanced enzymatic activities of PRMTs have been closely associated with pathological states such as cancer, inflammatory, immune, metabolic, and neurodegenerative diseases. Therefore, the development of inhibitors targeting PRMTs has attracted a great deal of attention in both pharmaceutical industries and academic community. This review focuses on the small-molecule inhibitors targeting PRMTs in cancer therapy in the patents published since 2019. The recent clinical development is also discussed here. In recent years, the discovery of small-molecule PRMT inhibitors, especially PRMT5 inhibitors has become a rapidly expanding research area for cancer therapy. Although a number of potent PRMT inhibitors with different chemical scaffolds have been developed and nine of them have entered into clinical trials, their scaffolds are relatively less diverse. Sub-type selectivity should be considered in drug discovery as nonselective inhibition of PRMTs may cause undesirable pharmacological effects. Hence, the development of new effective inhibitors with isoform-specific and tumor-biased distributions remains an important area for further studies.

13 February 2022 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
SHSuwen Hu
Suwen Hu
ZHZi Hui
Zi Hui
JDJilong Duan
Jilong Duan
GCGarrido Carmen
Garrido Carmen
TXTian Xie
Tian Xie
XYXiang-Yang Ye
Xiang-Yang Ye
Ataxia telangiectasia and RAD3-related kinase (ATR) is one of the key phosphatidylinositol 3-kinase-related kinase family members important for DNA damage response and repair pathways. Targeting AT...